^
    12d
    Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=32 --> 17
    Enrollment closed • Enrollment change
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • adrixetinib (Q702)
    4ms
    KEYNOTE-D35: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=120, Active, not recruiting, Qurient Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Mar 2028 | Trial primary completion date: Oct 2025 --> Dec 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • adrixetinib (Q702)
    4ms
    QRNT-012: Study of Q702 in Subjects with Relapsed or Refractory Chronic Graft-versus-Host Disease (cGVHD) (2025-522680-14-00)
    P1, N=16, Recruiting, Qurient Co. Ltd.
    New P1 trial
    |
    adrixetinib (Q702)
    5ms
    A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease (clinicaltrials.gov)
    P1, N=18, Recruiting, Qurient Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    adrixetinib (Q702)
    5ms
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=51, Completed, Qurient Co., Ltd. | Active, not recruiting --> Completed | N=78 --> 51 | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    adrixetinib (Q702)
    10ms
    A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Qurient Co., Ltd.
    New P1 trial
    |
    adrixetinib (Q702)
    over1year
    Phase I Study of Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=32, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2025
    Enrollment open • Trial initiation date
    |
    Venclexta (venetoclax) • azacitidine • adrixetinib (Q702)
    over1year
    Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Nov 2024 --> Nov 2025 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial initiation date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • adrixetinib (Q702)
    over1year
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, Qurient Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    adrixetinib (Q702)
    2years
    Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    Venclexta (venetoclax) • azacitidine • adrixetinib (Q702)
    2years
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=120, Recruiting, Qurient Co., Ltd. | Phase classification: P1b/2 --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • adrixetinib (Q702)
    over2years
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=78, Recruiting, Qurient Co., Ltd. | Trial completion date: Nov 2023 --> Feb 2025 | Trial primary completion date: Jul 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    adrixetinib (Q702)